Page 1 | Search Results | Blood | American Society of Hematology

1-14 of 14

Sort by

Sort Order Select

Journal Articles

Nilotinib Vs. Dasatinib in Achieving MR 4.5 for Newly Diagnosed Chronic Myeloid Leukemia: Results of the Prospective Randomized Phase 3 Study, JALSG CML212

Blood (2020) 136 (Supplement 1): 40–41.

https://doi.org/10.1182/blood-2020-134168

Published: 2020

Journal Articles

Interleukin 1 Beta As a Promising Therapeutic Target in ABL Tyrosine Kinase Inhibitor Resistant Chronic Myeloid Leukemia Cells

Seiichi Okabe, MD PhD, Tetsuzo Tauchi, MD PhD, Yuko Tanaka, Kazuma Ohyashiki, MD PhD

Blood (2018) 132 (Supplement 1): 4249.

https://doi.org/10.1182/blood-2018-99-114030

Published: 2018

Journal Articles

Targeting Insulin-like Growth Factor in Multiple Myeloma: Novel Strategies in the Treatment of Proteasome Inhibitor Resistant Cells

Yuko Tanaka, Seiichi Okabe, MD PhD, Tetsuzo Tauchi, MD PhD, Yoshikazu Ito, MD PhD, Kazuma Ohyashiki, MD PhD

Blood (2018) 132 (Supplement 1): 5155.

https://doi.org/10.1182/blood-2018-99-114750

Published: 2018

Journal Articles

Anti-Leukemic Effects of Venetoclax on Philadelphia Chromosome Positive Leukemia Cells

Seiichi Okabe, MD PhD, Tetsuzo Tauchi, MD PhD, Yuko Tanaka, MD PhD, Kazuma Ohyashiki, MD PhD

Blood (2016) 128 (22): 5428.

https://doi.org/10.1182/blood.V128.22.5428.5428

Published: 2016

Journal Articles

Anti-Leukemic Activity of Phosphoinositide 3-Kinase Inhibitor, Copanlisib in ABL Tyrosine Kinase Resistant Leukemia Cells

Seiichi Okabe, MD PhD, Tetsuzo Tauchi, MD PhD, Yuko Tanaka, MDPhD, Seiichiro Katagiri, MD PhD, Kazuma Ohyashiki

Blood (2014) 124 (21): 3127.

https://doi.org/10.1182/blood.V124.21.3127.3127

Published: 2014

Journal Articles

Antitumor Activity of Phosphoinositide 3-Kinases Inhibitor, Copanlisib in Multiple Myeloma Cells

Yuko Tanaka, MDPhD, Seiichi Okabe, MD PhD, Tetsuzo Tauchi, MD PhD, Yoshikazu Ito, MD PhD, Kazuma Ohyashiki

Blood (2014) 124 (21): 5755.

https://doi.org/10.1182/blood.V124.21.5755.5755

Published: 2014

Journal Articles

BCL2L11 ( BIM ) Deletion Polymorphism Is Associated with Molecular Relapse after ABL Tyrosine Kinase Inhibitor Discontinuation in Patients with Chronic Myeloid Leukemia with Complete Molecular Response

Seiichiro Katagiri, MD PhD, Tetsuzo Tauchi, MD PhD, Yuu Saito, MD, Tamiko Sugro, MD, Michiyo Asano, MD, Seiichiro Yoshizawa, MD PhD, Juri Sakuta, MD PhD, Daigo Akahane, MD PhD, Yuko Tanaka, MD PhD, Nahoko Furuya, MD PhD, Keiko Ando, MD PhD, Hiroaki Fujimoto, MD, Seiichi Okabe, MD PhD, Moritaka Gotoh, MD PhD, Yoshikazu Ito, MD PhD, Tomohiro Umezu, PhD, Junko H Ohyashiki, MD PhD, Kazuma Ohyashiki, MD PhD

Blood (2014) 124 (21): 1797.

https://doi.org/10.1182/blood.V124.21.1797.1797

Published: 2014

Journal Articles

Activity of the Stemness Inhibitor, BBI608, on the Self-Renewal of BCR-ABL1 Positive Leukemia Cells: Molecular Mechanisms

Tetsuzo Tauchi, MD PhD, Seiichiro Katagiri, MD, Seiichi Okabe, MD PhD, Yuko Tanaka, MDPhD, Kazuma Ohyashiki, MD, PhD

Blood (2014) 124 (21): 905.

https://doi.org/10.1182/blood.V124.21.905.905

Published: 2014

Journal Articles

Combining ABL1 Kinase Inhibitor, Ponatinib and the Histone Deacetylase (HDAC) Inhibitor Vorinostat: A Potential Treatment for BCR-ABL Positive Leukemia Cells

Seiichi Okabe, M.D., Tetsuzo Tauchi, MD, PhD, Shinya Kimura, MD, PhD, Taira Maekawa, MD, PhD, Kazuma Ohyashiki, MD, PhD

Blood (2011) 118 (21): 1403.

https://doi.org/10.1182/blood.V118.21.1403.1403

Published: 2011

Journal Articles

Efficacy of Ponatinib Against ABL Tyrosine Kinase Inhibitor Resistant Leukemia Cells

Seiichi Okabe, M.D., Tetsuzo Tauchi, MD, PhD, Kazuma Ohyashiki, MD, PhD

Blood (2011) 118 (21): 4413.

https://doi.org/10.1182/blood.V118.21.4413.4413

Published: 2011

Journal Articles

Increased NK Cells and Decreased CD3 + CD8 + CD62L + T Cells in CML Patients Who Sustained Complete Molecular Remission After Discontinuation of Imatinib

Kazuma Ohyashiki, MD, PhD, Sei-ichiro Katagiri, MD, Tetsuzo Tauchi, MD, PhD, Junko H Ohyashiki, MD, PhD, Yasuhiro Maeda, MD, PhD, Itaru Matsumura, MD, PhD, Taiichi Kyo, MD

Blood (2011) 118 (21): 1697.

https://doi.org/10.1182/blood.V118.21.1697.1697

Published: 2011

Journal Articles

Combined Effects of novel Heat Shock Protein 90 Inhibitor NVP-AUY922 and Nilotinib in a Random Mutagenesis Screen.

Tetsuzo Tauchi, MD, PhD, Seiichi Okabe, MD, PhD, Eishi Ashihara, MD, PhD, Shinya Kimura, MD, PhD, Taira Maekawa, MD, PhD, Kazuma Ohyashiki, MD, PhD

Blood (2009) 114 (22): 3765.

https://doi.org/10.1182/blood.V114.22.3765.3765

Published: 2009

Journal Articles

The Efficacy of Dual PI3K and mTOR Inhibitor, NVP-BEZ235 against BCR-ABL Positive Leukemia Cells Include ABL Kinase Domain Mutation in Combination with Nilotinib.

Seiichi Okabe, MD, PhD, Tetsuzo Tauchi, MD, PhD, Shinya Kimura, MD, PhD, Taira Maekawa, MD, PhD, Kazuma Ohyashiki, MD, PhD

Blood (2009) 114 (22): 3784.

https://doi.org/10.1182/blood.V114.22.3784.3784

Published: 2009

Journal Articles

Combined Effects of Novel Heat Shock Protein 90 Inhibitor NVP-AUY922 and Nilotinib against Mutant Forms of BCR-ABL

Tetsuzo Tauchi, MD, PhD, Daigo Akahane, MD, Seiichi Okabe, MD, PhD, Eishi Ashihara, MD, Shinya Kimura, MD, PhD, Taira Maekawa, MD, PhD, Kazuma Ohyashiki, MD, PhD

Blood (2008) 112 (11): 724.

https://doi.org/10.1182/blood.V112.11.724.724

Published: 2008

NARROW

Nilotinib Vs. Dasatinib in Achieving MR 4.5 for Newly Diagnosed Chronic Myeloid Leukemia: Results of the Prospective Randomized Phase 3 Study, JALSG CML212

Interleukin 1 Beta As a Promising Therapeutic Target in ABL Tyrosine Kinase Inhibitor Resistant Chronic Myeloid Leukemia Cells

Targeting Insulin-like Growth Factor in Multiple Myeloma: Novel Strategies in the Treatment of Proteasome Inhibitor Resistant Cells

Anti-Leukemic Effects of Venetoclax on Philadelphia Chromosome Positive Leukemia Cells

Anti-Leukemic Activity of Phosphoinositide 3-Kinase Inhibitor, Copanlisib in ABL Tyrosine Kinase Resistant Leukemia Cells

Antitumor Activity of Phosphoinositide 3-Kinases Inhibitor, Copanlisib in Multiple Myeloma Cells

BCL2L11 ( BIM ) Deletion Polymorphism Is Associated with Molecular Relapse after ABL Tyrosine Kinase Inhibitor Discontinuation in Patients with Chronic Myeloid Leukemia with Complete Molecular Response

Activity of the Stemness Inhibitor, BBI608, on the Self-Renewal of BCR-ABL1 Positive Leukemia Cells: Molecular Mechanisms

Combining ABL1 Kinase Inhibitor, Ponatinib and the Histone Deacetylase (HDAC) Inhibitor Vorinostat: A Potential Treatment for BCR-ABL Positive Leukemia Cells

Efficacy of Ponatinib Against ABL Tyrosine Kinase Inhibitor Resistant Leukemia Cells

Increased NK Cells and Decreased CD3 + CD8 + CD62L + T Cells in CML Patients Who Sustained Complete Molecular Remission After Discontinuation of Imatinib

Combined Effects of novel Heat Shock Protein 90 Inhibitor NVP-AUY922 and Nilotinib in a Random Mutagenesis Screen.

The Efficacy of Dual PI3K and mTOR Inhibitor, NVP-BEZ235 against BCR-ABL Positive Leukemia Cells Include ABL Kinase Domain Mutation in Combination with Nilotinib.

Combined Effects of Novel Heat Shock Protein 90 Inhibitor NVP-AUY922 and Nilotinib against Mutant Forms of BCR-ABL

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only